KLRC1 and neoplasm: Monalizumab is an anti-NKG2A blocking mAb that not only boosts NKG2A+NK cell responses against HLA-E+ tumor cells but also promotes the effectiveness of durvalumab (a mAb that blocks PD-L1) by increasing the functional activity of NKG2A+PD-1+ NK cells against HLA-E+PD-L1+ target cells.